Bello Roufai D, Goncalves A, De La Motte Rouge T, Akla S, et al. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023 Mar 15. doi: 10.1038/s41388-023-02615.
PMID: 36922682